Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|June 9, 2015
DIA Appoints Co-Chairs for 2016 EuroMeeting in Hamburg
Author(s)Philip Ward
The congress will be held at the Congress Center Hamburg (CCH) in Germany on 6 to 8 April 2016. For the first time, it will feature one or more sessions on medical writing.
Advertisement
Karl Broich, President of the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) in Germany, and Kemal Malik, a member of the board of management at Bayer AG in Germany, will be the co-chairs of the 28th Drug Information Association (DIA) EuroMeeting.
The congress will be held at the Congress Center Hamburg (CCH) in Germany on 6 to 8 April 2016. For the first time, it will feature one or more sessions on medical writing.
The call for abstracts for presentations, full sessions and tutorials is open until 29 June. Applicants may submit more than one abstract, and they should cover innovation, clinical research, clinical trials, regulatory science, medical affairs, eHealth/big data, pharmacovigilance, lifecycle benefit/risk management, availability of medicinal products, globalization, medical devices and combination products, and health tech assessment.
According to a statement on the DIA web site, the main aim of the 2016 EuroMeeting will be “to provide a platform for experts from all relevant disciplines within the entire healthcare development and access process to debate and find solutions to some of the most pertinent challenges faced in an ever-evolving healthcare system - including the need to drive innovation.”
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
3
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5